AstraZeneca Reveals Treatment Plus Chemotherapy Reduced Disease Progression by 38% for Advanced NSCLC Patients in FLAURA2 Phase III Trial
Arun Krishna, VP, Head of Lung Cancer Franchise, US Oncology Business Unit at AstraZeneca discusses the positive results from the FLAURA2 Phase III trial of TAGRISSO ® (osimertinib) plus chemotherapy and its significance as a new potential treatment option for patients with advanced lung cancer.
Arun Krishna, Vice President, Head of Lung Cancer Franchise, US Oncology Business Unit, is responsible for overseeing all lung cancer US sales and the commercialization of TAGRISSO and future lung cancer indications.
Prior Experience
Before assuming his current role in 2022, Arun was the Head of Oncology in the UK where he led an integrated team across Commercial, Medical, Access, Diagnostics & Business Innovation in five therapeutic areas. Prior to joining AstraZeneca in 2019 he held various clinical development, new product strategy and market access roles at Novartis and Merck.
